BACKGROUND: There is considerable variability in the amount of response to BTX-A
treatment between and within patients with cerebral palsy (CP). AIMS: The purpose of this …

Objectives In the last 2 decades, BTX-A is increasingly being used in the management of
spasticity in children with Cerebral Palsy (CP) and there is no doubt about its effect on range …

Objective: To assess the safety of botulinum toxin type A for children with cerebral palsy
using data from randomized clinical trials. Data sources: A search was conducted of …

Objective To examine the safety and efficacy of abobotulinumtoxinA in patients previously
treated with botulinum toxin type A (BoNT‐A) products other than abobotulinumtoxinA …

The use of Botulinum toxin (BoNT) in the treatment of focal spasticity in adults and children
has become well established worldwide. Since the first use of BoNT in children with spastic …

Purpose The aim of this study was to assess the effectiveness of long-term therapy with
multiply botulinum neurotoxin (BoNT) injections. Methods In 2004–2010, 60 children with …

Abstract Botulinum toxin A (BTX-A) is widely used worldwide to overcome the significant
problem in spastic cerebral palsy (CP). In the past three decades, botulinum toxin serotype A …

Botulinum toxin A is widely used for spasticity management in children with cerebral palsy,
although outcomes are unpredictable. The aim of this study was to identify criteria for …

The efficacy of botulinum toxin A in the treatment of spasticity in ambulant children with cerebral
palsy: a structured review - Database of Abstracts of Reviews of Effects (DARE) …

Background Intramuscular injections of botulinum toxin A (BoNT-A) have been a
cornerstone in the treatment of spasticity for the last 20 years. In Norway, the treatment is …